Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AL
Alector, Inc. Common Stock
ALEC
Mkt Cap
$204.9M
Volume
4.86M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AL
ALEC
AL
Alector, Inc. Common Stock
ALEC
News
·
Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034
Mkt Cap
$213.3M
Volume
4.86M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034
The dementia therapeutics market is experiencing significant growth driven by emerging disease-modifying treatments for early-stage Alzheimer's and promising therapies for other dementia subtypes. With approximately 55 million people globally affected by dementia, the market is shifting toward proactive intervention with drugs like LEQEMBI and KISUNLA leading the way, while the pipeline shows promise with novel agents targeting diverse symptoms and unmet needs.
GlobeNewswire Inc. · Apr 13, 2026
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Alector's Phase 3 clinical trial for latozinemab in frontotemporal dementia failed to meet primary endpoints, causing a 50% stock price drop and triggering a potential shareholder lawsuit.
GlobeNewswire Inc. · Nov 26, 2025
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic
Biotechnology company Alector announced that its drug latozinemab did not meet safety and efficacy criteria in a Phase 3 clinical trial for treating frontotemporal dementia (FTD) caused by GRN gene variants. Despite increasing progranulin protein levels, the drug did not slow disease progression.
GlobeNewswire Inc. · Oct 21, 2025
Alector to Participate in Upcoming Healthcare Conferences
Alector, a late-stage clinical biotechnology company, announced that it will participate in upcoming investor conferences, where it will present its therapies for neurodegenerative diseases.
GlobeNewswire Inc. · Feb 25, 2025
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
Alector, a late-stage clinical biotechnology company, provided an update on its pipeline, including the anticipated topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation, and the ongoing PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease. The company also highlighted its preclinical and research pipeline, including programs leveraging its Alector Brain Carrier technology.
GlobeNewswire Inc. · Jan 13, 2025
Alector to Participate in Upcoming Healthcare Conferences
Alector, a clinical-stage biotechnology company, announced that it will participate in several upcoming investor conferences, including the Morgan Stanley 22nd Annual Global Healthcare Conference, the H.C. Wainwright 26th Annual Global Investment Conference, and the 2024 Cantor Global Healthcare Conference.
GlobeNewswire Inc. · Aug 29, 2024
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of its TREM2 agonist AL002 in early Alzheimer's disease. The trial enrolled a representative population, allowing for testing of the novel TREM2 agonist.
GlobeNewswire Inc. · Jul 28, 2024
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks Investment Research · Jun 24, 2024
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
GlobeNewswire Inc. · Jun 10, 2024
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
GlobeNewswire Inc. · May 9, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AL
ALEC
Alector, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ALEC
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ALEC yet.
Related Tickers
Earnings